Recently, de novo heterozygous FOXA2 mutations have been reported in patients with the clinical phenotype of congenital hypopituitarism, hyperinsulinism, hypoglycemia, and endometrial‐derived organ abnormalities (Giri et al., 2017; Tsai et al., 2015; Vajravelu et al., 2018). Here, FOXA2 is linked to hypopituitarism.